Finance

Lists
KROS:NASDAQ
Keros Therapeutics Inc
$10.93
+1.58%
(+0.17) 1D
Nov 3, 12:04:36 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
$10.78
High
$11.11
Low
$10.78
Mkt. cap
216.71M
Avg. vol.
170.41K
Volume
30.82K
52-wk high
$22.55
52-wk low
$9.69
EPS
-$3.70
Beta
1.13
Shares outstanding
19.83M
No. of employees
92
Open
$10.78
High
$11.11
Low
$10.78
Mkt. cap
216.71M
Avg. vol.
170.41K
Volume
30.82K
52-wk high
$22.55
52-wk low
$9.69
EPS
-$3.70
Beta
1.13
Shares outstanding
19.83M
No. of employees
92
News stories
From web sources and news partners
About Keros Therapeutics Inc
CEO-
Employees92
Founded2015
HeadquartersLexington, Massachusetts, United States
SectorBiotechnology
Websitekerostx.com
Analyst ratings
Based on 6 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
3
Hold
3
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current $10.93
$23.00 (+110.43%)
Average
$18.80 (+72.00%)
Lowest
$16.00 (+46.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Benjamin Burnett
Wells Fargo
Buy
Maintained
$18.00
+64.7%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
$17.00
+55.5%
08/11/2026
Yun Zhong
Wedbush
Hold
Maintained
$16.00
+46.4%
08/04/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$20.00
+83%
08/04/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
$23.00
+110.4%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$27.00
+147%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$30.00
+174.5%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
$20.00
+83%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
14.26M
385.00K
367.00K
-
Cost of goods sold
19.52M
17.81M
16.10M
22.33M
Cost of revenue
19.52M
17.81M
16.10M
22.33M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.13M
11.74M
10.15M
8.61M
Operating expense
10.13M
11.74M
10.15M
8.61M
Total operating expenses
29.65M
29.56M
26.24M
30.94M
Operating income
-15.38M
-29.17M
-25.88M
-30.94M
Other non operating income
-
-539.00K
-
-60.00K
EBT including unusual items
-8.70M
-24.98M
-23.71M
-28.71M
EBT excluding unusual items
-8.70M
-24.88M
-23.71M
-28.71M
Income tax expense
-1.42M
-1.51M
-
-
Effective tax rate
16.36%
6.06%
-
-
Other operating expenses
-
-
-
-
Net income
-7.28M
-23.46M
-23.71M
-28.71M
Net profit margin
-51.04%
-6,093.77%
-6,459.95%
-
Earnings per share
-0.18
-0.86
-1.21
-1.45
Interest and investment income
6.93M
4.02M
2.34M
2.29M
Interest expense
-
-
-
-
Net interest expenses
6.93M
4.02M
2.34M
2.29M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.99M
-28.77M
-25.47M
-30.54M
Gain or loss from assets sale
-
1.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps